Intra Cellular Therapies, Inc. ITCI
We take great care to ensure that the data presented and summarized in this overview for Intra-Cellular Therapies, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ITCI
View all-
Vanguard Group Inc Valley Forge, PA9.63MShares$1.22 Billion0.01% of portfolio
-
Black Rock Inc. New York, NY6.32MShares$803 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY5.29MShares$671 Million0.03% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT3.85MShares$489 Million1.4% of portfolio
-
Avoro Capital Advisors LLC New York, NY3.05MShares$387 Million3.36% of portfolio
-
Invesco Ltd. Atlanta, GA2.99MShares$380 Million0.04% of portfolio
-
Bellevue Group Ag Kuesnacht, V82.49MShares$316 Million3.06% of portfolio
-
State Street Corp Boston, MA1.86MShares$236 Million0.01% of portfolio
-
Franklin Resources Inc San Mateo, CA1.75MShares$223 Million0.04% of portfolio
-
Clearbridge Investments, LLC New York, NY1.73MShares$220 Million0.1% of portfolio
Latest Institutional Activity in ITCI
Top Purchases
Top Sells
About ITCI
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder; and in additional neuropsychiatric indications, such as sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease and heart failure; ITI-1284-ODT-SL for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.
Insider Transactions at ITCI
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 31
2025
|
Mark Neumann EVP, Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,729
-11.61%
|
$600,583
$127.0 P/Share
|
|
Jan 31
2025
|
Mark Neumann EVP, Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,017
+21.3%
|
-
|
|
Jan 31
2025
|
Michael Halstead President |
SELL
Payment of exercise price or tax liability
|
Direct |
5,691
-51.66%
|
$722,757
$127.0 P/Share
|
|
Jan 31
2025
|
Michael Halstead President |
BUY
Grant, award, or other acquisition
|
Direct |
11,017
+50.0%
|
-
|
|
Jan 31
2025
|
Sharon Mates Chairman and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
15,233
-1.38%
|
$1,934,591
$127.0 P/Share
|
|
Jan 31
2025
|
Sharon Mates Chairman and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
30,847
+2.72%
|
-
|
|
Jan 31
2025
|
Suresh K. Durgam EVP, Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,730
-15.35%
|
$600,710
$127.0 P/Share
|
|
Jan 31
2025
|
Suresh K. Durgam EVP, Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,017
+26.33%
|
-
|
|
Dec 31
2024
|
Rory B Riggs |
BUY
Grant, award, or other acquisition
|
Direct |
215
+0.16%
|
$17,845
$83.52 P/Share
|
|
Dec 05
2024
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
51,697
-2.31%
|
$4,342,548
$84.38 P/Share
|
|
Dec 05
2024
|
Sharon Mates Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
51,697
+4.4%
|
$620,364
$12.73 P/Share
|
|
Dec 04
2024
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
51,000
-2.3%
|
$4,335,000
$85.81 P/Share
|
|
Dec 04
2024
|
Sharon Mates Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
51,000
+4.35%
|
$612,000
$12.73 P/Share
|
|
Nov 13
2024
|
Michael Halstead President |
SELL
Open market or private sale
|
Direct |
18,714
-85.72%
|
$1,646,832
$88.54 P/Share
|
|
Nov 13
2024
|
Michael Halstead President |
BUY
Exercise of conversion of derivative security
|
Direct |
18,714
+50.0%
|
$673,704
$36.89 P/Share
|
|
Nov 12
2024
|
Michael Halstead President |
SELL
Open market or private sale
|
Direct |
22,869
-81.61%
|
$2,035,341
$89.75 P/Share
|
|
Nov 12
2024
|
Michael Halstead President |
BUY
Exercise of conversion of derivative security
|
Direct |
22,869
+50.0%
|
$525,987
$23.94 P/Share
|
|
Sep 30
2024
|
Rory B Riggs |
BUY
Grant, award, or other acquisition
|
Direct |
246
+0.21%
|
$17,958
$73.17 P/Share
|
|
Aug 30
2024
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
34,396
-1.56%
|
$2,510,908
$73.03 P/Share
|
|
Aug 30
2024
|
Sharon Mates Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
34,396
+3.02%
|
$412,752
$12.73 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 799K shares |
|---|---|
| Grant, award, or other acquisition | 65K shares |
| Open market or private sale | 712K shares |
|---|---|
| Payment of exercise price or tax liability | 30.4K shares |